Based on the premise that Nox2 plays a major role in oxidative damage and exacerbates neurodegenerative diseases, we envision applications of brain-permeable Nox2 inhibitors in mechanistic studies in vivo, and, long-term, in the development of novel therapeutic strategies. Here, CYBB is linked to neurodegenerative disease.